Shopping Cart

Your shopping cart is currently empty

Ulipristal acetate

Name: Ulipristal acetate
Brand: TargetMol
SKU: T2527
Price: 45 USD
Availability: InStock
Rating: 5 (10 reviews)

🥰Excellent

Catalog No. T2527Cas No. 126784-99-4

Alias Ulipristal, CDB-2914

Ulipristal acetate (CDB-2914) is an orally bioavailable selective progesterone receptor modulator with anti-progesterone activity. It binds to the progesterone receptor (PR), inhibiting PR-mediated gene expression and interfering with progesterone activity in the reproductive system, potentially suppressing the growth of uterine leiomyomatosis. Additionally, ulipristal can be used as emergency contraception by inhibiting or delaying ovulation and affecting endometrial tissue.

Ulipristal acetate

🥰Excellent

Purity: 99.94%

Catalog No. T2527Alias Ulipristal, CDB-2914Cas No. 126784-99-4

Pack Size	Price	USA Warehouse	Global Warehouse
5 mg	$45	In Stock	In Stock
10 mg	$61	In Stock	In Stock
50 mg	$126	In Stock	In Stock
100 mg	$198	In Stock	In Stock
200 mg	$297	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$51	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.94%

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	Ulipristal acetate (CDB-2914) is an orally bioavailable selective progesterone receptor modulator with anti-progesterone activity. It binds to the progesterone receptor (PR), inhibiting PR-mediated gene expression and interfering with progesterone activity in the reproductive system, potentially suppressing the growth of uterine leiomyomatosis. Additionally, ulipristal can be used as emergency contraception by inhibiting or delaying ovulation and affecting endometrial tissue.
In vitro	Ulipristal acetate blocks activin A modulation of fibronectin and vascular endothelial growth factor A (VEGF-A) mRNA expression in cultured myometrial and leiomyoma cells[2]. Ulipristal acetate decreases the DNA fragmentation at the 100-ng/mL dose and continuing up to the 10,000-ng/mL dose compared to those spermatozoa in the control group[3].
In vivo	Ulipristal and CDB-4124 exhibit notable antiprogestational effects in vivo[1]. Ulipristal acetate has been shown to reduce the occurrence of fibroadenomas and adenocarcinomas in the mammary glands across all groups studied. At the highest administered dose in rats, ulipristal acetate exposure [AUC(0-24h)] is 67 times the human therapeutic exposure at 10 mg/day. Importantly, in mice, ulipristal acetate does not lead to an increase in tumor formation, even at exposures up to 313 times the therapeutic level. Adverse effects in mice are confined to weight changes in specific organs (liver, pituitary, thyroid/parathyroid glands, and epididymis) and minimal panlobular hepatocellular hypertrophy at a dose of 130 mg/kg/day[4]. Additionally, ulipristal acetate at doses of 1 mg/kg and 5 mg/kg causes a dose-dependent increase in endometrial thickening, observed by pathologists more frequently than in controls. There is also a minor decrease in secretory differentiation as the dose of ulipristal acetate increases, indicated by reduced sub- and supra-nuclear vacuolation[5].
Synonyms	Ulipristal, CDB-2914

Chemical Properties

Molecular Weight	475.62
Formula	C₃₀H₃₇NO₄
Cas No.	126784-99-4
Smiles	CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12
Relative Density.	1.19 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 50 mg/mL (105.13 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.21 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.1025 mL	10.5126 mL	21.0252 mL	105.1259 mL
5 mM	0.4205 mL	2.1025 mL	4.2050 mL	21.0252 mL
10 mM	0.2103 mL	1.0513 mL	2.1025 mL	10.5126 mL
20 mM	0.1051 mL	0.5256 mL	1.0513 mL	5.2563 mL
50 mM	0.0421 mL	0.2103 mL	0.4205 mL	2.1025 mL
100 mM	0.0210 mL	0.1051 mL	0.2103 mL	1.0513 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc